Navigation Links
FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Date:2/4/2011

WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA).

Regorafenib is an investigational agent and is not approved by the FDA, the European Medicines Agency (EMA) or other Health Authorities.

"This is an important step in the overall development process for this investigational compound," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee.

In January, Bayer began enrolling patients in a randomized, double-blind, placebo-controlled Phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib (NCT01271712). The trial is estimated to enroll 170 patients, who will be randomized in a 2:1 ratio to receive either regorafenib or placebo. Subjects receiving placebo who experience disease progression may be offered open-label regorafenib treatment (cross-over option).

The primary endpoint of this trial is progression-free survival (PFS), and secondary endpoints include overall survival (OS), time to progression (TTP), disease control rate (DCR), tumor response rate (RR), duration of response (DOR), and safety. All patients will enter the Survival Follow-Up Period upon discontinuation of study treatment, during which assessment of survival status will be performed every three months.

For information about this study, please visit www.clinicaltrials.gov (NCT01271712).

Orphan Drug Designation in the United States

In the United States, the Orphan Drugs Act (OD
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Belgium and NEW YORK , October ... Contract Research Organization (CRO) and service provider for the medical industries, ... opening of offices in New York City . ... York City is strategically centered in one of the ... East Coast", said Philippe Kassab , President at genae Americas. ...
(Date:10/1/2014)... --  Cypher Genomics, Inc., the genome informatics company, ... as chief technology officer. Ravenel has more than ... a proven track record of designing and architecting solutions ... been recognized as a top designer and architect of ... for delivering innovative products that operate at scale and ...
(Date:10/1/2014)... SAN JOSE, Calif. , Oct. 1, 2014  SI-BONE, ... the iFuse Implant System, ® a minimally invasive surgical ... sacroiliac (SI) joint, today announced the expansion of its European ... of Mr. Eric Schaber as General Manager, Germany.  ... , currently vice president of Europe , ...
Breaking Medicine Technology:genae Opens Offices in New York City 2Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... company at the Bank of America Merrill Lynch Healthcare conference in ... Las Vegas, NV Presentation date: Tuesday May 10, 2011 ... A live webcast and 30-day archive of this presentation ...
... MELVILLE, N.Y., May 3, 2011 Henry Schein, ... healthcare products and services to office-based practitioners, today reported record ... Net sales for the first quarter of 2011 were ... quarter of 2010.  This consists of 9.9% growth in local ...
Cached Medicine Technology:Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new NoteSwift™ 2.0 ... NoteSwift is the bridge between the EHR and Dragon ... clinical information at the point of care. NoteSwift reduces ... by more than half – and virtually eliminates mouse ... state impedes EHR use according to the June 12, ...
(Date:10/1/2014)... 01, 2014 Nordic Naturals is ... very special cause. The campaign—“Buy One Bottle. Help ... for Veterans, a nonprofit organization that helps rebuild ... shelter dogs that would otherwise face euthanasia. From ... will support monthly donations of Nordic Naturals omega-3s ...
(Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2
... hope to detect the disease while it is still ... scientists say they have found small molecules in the ... could have diagnostic implications in the future. , Levels ... suffering from pancreatic cancer, the fourth-leading cancer killer in ...
... harsh skin toxicity associated with a widely used cancer drug, ... Cancer Biology and Therapy by researchers from City of ... (Erbitux) is a monoclonal antibody that binds to and inhibits ... to treat colorectal cancer and head and neck cancer. Although ...
... combined with a defibrillator (CRT-D) implanted had a 34 ... failure when compared to patients receiving only an implanted ... online today in the New England Journal of ... of Cardiology Congress (ESC) in Barcelona, Spain. The overall ...
... is available in French . , ... serious autoimmune disorders which cause muscular inflammation are at ... of Montreal researchers. Dr. Christian A. Pineau and his ... Health Centre (RI-MUHC) have linked muscular inflammation to increased ...
... , , , , ... in grants for four Northwest nonprofits: HealthMatters of Central Oregon ... Northwest Organization of Nurse Executives . The grants all ... increase access to care. , , "At The Regence ...
... , PITTSBURGH, Sept. 1 On Friday, September 18, ... former president of the renowned public relations agency Porter Novelli, former ... native William (Bill) D. Novelli. Enjoy lunch and a presentation ... to accomplish this, and what it means for seniors in the ...
Cached Medicine News:Health News:Blood Test May Spot Pancreatic Cancer Early 2Health News:Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs 2Health News:Stuy in NEJM: New therapy prevents heart failure 2Health News:Researchers link inflammatory diseases to increased cardiovascular risk 2Health News:Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits 2
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: